Home / Healthcare/ GSK’s new triple lung drug beats other modern inhalers in study

GSK’s new triple lung drug beats other modern inhalers in study


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 27 September 2017 00:00


London (Reuters): GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments.

Britain’s biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair.

Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZeneca’s long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

The latest clinical trial, however, compares Trelegy to two more modern two-drug combinations and was seen as a more critical test for doctors wanting to know if the new product really delivers an added benefit.

The IMPACT study, which involved 10,355 patients, showed Trelegy delivered statistically significant reductions in the rate of annual exacerbations, or attacks, compared with both Breo and Anoro, two other relatively new GSK medicines.

GSK and its partner Innoviva plan to submit the latest data from the so-called IMPACT trial to regulatory authorities from the second quarter of 2018, with the aim of expanding the indicated patient population for Trelegy.


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

In the desert of Tamil films, actor Sivaji Ganesan was an oasis

Saturday, 22 September 2018

‘Indian Film,’ first published in 1963 and co-authored by former Columbia University Professor Erik Barnouw and his student Dr. Subrahmanyam Krishnaswamy, is considered a seminal study of the evolution and growth of Indian cinema. The book is cit


Imran may turn blind eye to blasphemy law and persecution of Ahmadiyyas

Saturday, 22 September 2018

There are clear signs that Pakistan’s freshly minted Prime Minister, Imran Khan, will make a sincere effort to reduce corruption and maladministration in the domestic sphere. In foreign affairs he is likely to make a brave attempt to mend fences wi


The rate of exchange, capital flight and the Central Bank

Friday, 21 September 2018

The Central Bank (CBSL) exists for the sole purpose of price stability. Its controls on the financial system and monetary policy exist to maintain price stability. As put forth many times by the Governor, the failing of the CBSL to control inflation


Red flag over the Sri Lankan Navy

Friday, 21 September 2018

Shocking story Rusiripala, a former banker in Sri Lanka, who has taken to writing in Daily FT, is perturbed by the red flag I have raised (Daily FT article 18 September) over the shocking charge that our Navy had operated a ransom gang that had abduc


Columnists More